ENTITY

Adaptimmune Therapeutics (ADAP US)

Analysis

Health Care • United States

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company develops novel cancer immunotherapy products based on T-cell receptor platform that helps to identify cancer targets. Adaptimmune Therapeutics serves customers worldwide.

Refresh

Focused

No publications yet

There aren’t any Insights right now

Back to "All"

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00